SK Biopharmaceuticals Co., Ltd. (326030.KS)
KRW 103600.0
(-2.54%)
KRW 103600.0
(-2.54%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -61.64 Billion KRW | -218.93% |
| 2022 | 51.83 Billion KRW | 124.66% |
| 2021 | -210.18 Billion KRW | -414.46% |
| 2020 | -40.85 Billion KRW | -170.54% |
| 2019 | 57.91 Billion KRW | 177.95% |
| 2018 | -74.29 Billion KRW | -193.97% |
| 2017 | -25.27 Billion KRW | 34.55% |
| 2016 | -38.61 Billion KRW | 43.68% |
| 2015 | -68.56 Billion KRW | -142.87% |
| 2014 | -28.23 Billion KRW | -0.15% |
| 2013 | -28.19 Billion KRW | 21.13% |
| 2012 | -35.74 Billion KRW | 1.87% |
| 2011 | -36.42 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -78.62 Billion KRW | 7.05% |
| 2024 Q1 | -84.59 Billion KRW | -37.21% |
| 2023 Q1 | 52.86 Billion KRW | 1.99% |
| 2023 Q2 | 49.19 Billion KRW | -6.95% |
| 2023 Q3 | -90.44 Billion KRW | -283.85% |
| 2023 Q4 | -61.64 Billion KRW | 31.84% |
| 2023 FY | -61.64 Billion KRW | -218.93% |
| 2022 Q2 | -53.96 Billion KRW | 53.0% |
| 2022 FY | 51.83 Billion KRW | 124.66% |
| 2022 Q4 | 51.83 Billion KRW | 9.14% |
| 2022 Q3 | 47.49 Billion KRW | 188.02% |
| 2022 Q1 | -114.81 Billion KRW | 45.37% |
| 2021 FY | -210.18 Billion KRW | -414.46% |
| 2021 Q3 | -236.11 Billion KRW | -116.71% |
| 2021 Q2 | -108.95 Billion KRW | 34.12% |
| 2021 Q1 | -165.37 Billion KRW | -304.79% |
| 2021 Q4 | -210.18 Billion KRW | 10.98% |
| 2020 FY | -40.85 Billion KRW | -170.54% |
| 2020 Q2 | -365.35 Billion KRW | -463.3% |
| 2020 Q4 | -40.85 Billion KRW | 46.13% |
| 2020 Q3 | -75.84 Billion KRW | 79.24% |
| 2020 Q1 | 100.56 Billion KRW | 73.64% |
| 2019 Q4 | 57.91 Billion KRW | 0.0% |
| 2019 FY | 57.91 Billion KRW | 177.95% |
| 2018 FY | -74.29 Billion KRW | -193.97% |
| 2017 FY | -25.27 Billion KRW | 34.55% |
| 2016 FY | -38.61 Billion KRW | 43.68% |
| 2015 FY | -68.56 Billion KRW | -142.87% |
| 2014 FY | -28.23 Billion KRW | -0.15% |
| 2013 FY | -28.19 Billion KRW | 21.13% |
| 2012 FY | -35.74 Billion KRW | 1.87% |
| 2011 FY | -36.42 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | -3.06 Billion KRW | -1908.644% |
| Green Cross Holdings Corporation | 1105.62 Billion KRW | 105.576% |
| Green Cross Holdings Corporation | 674.31 Billion KRW | 109.143% |
| Pharmicell Co., Ltd. | -10.69 Billion KRW | -476.365% |
| Green Cross Corporation | 674.31 Billion KRW | 109.143% |
| GeneOne Life Science, Inc. | 8.04 Billion KRW | 865.956% |
| Celltrion, Inc. | 1325.8 Billion KRW | 104.65% |
| Samsung Biologics Co.,Ltd. | 1541.39 Billion KRW | 104.0% |
| SK bioscience Co.,Ltd. | -106.45 Billion KRW | 42.087% |
| Prestige BioPharma Limited | -129.76 Billion KRW | 52.491% |